Get started
Author

Len Reyno

Observed institution: C4 Therapeutics (United States)
OpenAlex ID: A5004366341
A phase 1a dose-escalation study of PY314, a TREM2 (Triggering Receptor Expressed on Macrophages 2) targeting monoclonal antibody.
2022 · Amita Patnaik, Erika P. Hamilton, et al. · Journal of Clinical Oncology · 17
A phase 1a dose-escalation study of PY159, a monoclonal antibody targeting TREM1 (triggering receptor expressed on myeloid cells 1).
2023 · Ira Seth Winer, Amita Patnaik, et al. · Journal of Clinical Oncology · 3
PDF
Abstract LB071: Tuning the tumor myeloid microenvironment (TME) by targeting TREM2+ tumor-associated macrophages to overcome resistance to immune checkpoint inhibitors
2021 · Nadine S. Jahchan, Mikhail Binnewies, et al. · Cancer Research · 3
Safety of the BRD9 heterobifunctional degrader CFT8634 in synovial sarcoma and SMARCB1-null tumors: an open-label, dose-escalation, phase 1 clinical trial
2026 · Brian A. Van Tine, William D. Tap, et al. · Communications Medicine
PDF
Works count: 4
Citation count: 23
H-index: 3
I10-index: 1
Year
Topic
Type